National Institute on Drug Abuse (NIDA)
Trial Pipeline
Environment and Alcohol: A Pilot Study
NCT06860607
Developing Transcranial Neuromodulation Protocols for Learning and Decision-Making
NCT06561828
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
NCT06676059
Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP
NCT06552741
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
NCT06233799
Semaglutide Therapy for Alcohol Reduction (STAR)
NCT06015893
Spironolactone in Alcohol Use Disorder (SAUD)
NCT05807139
Development and Validation of Learning and Decision-Making Tasks
NCT05707806
Orexin s Role in the Neurobiology of Substance Use Disorder
NCT05630781
Defining Neurobiological Links Between Substance Use and Mental Illness
NCT05538910
Evaluation of the Interactions of Cannabidiol (CBD) With Morphine
NCT05143424
Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder
NCT03745339
Mechanism of Non-invasive Magnetic Stimulation
NCT03394066
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
NCT01036581
SXC-2023 Cocaine Interaction Study
NCT06343532
Exploring Gut-Brain and Brain-Gut Interactions in Alcohol Use Disorder Via Microbiota Investigations: A Pilot Study
NCT03152760
Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin
NCT02393599
Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans
NCT02225184
Nicotine Withdrawal Symptoms and Smoking Relapse
NCT01511614
Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana
NCT01844687
Individual Differences in Reward and Impulse Control
NCT01621607
Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms
NCT01505725
Risk Perception in Drug-Dependent Adults With and Without Schizophrenia
NCT01031563
Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual Reality
NCT01031433
Vigabatrin Ph 1 Cocaine Interaction Study
NCT00626834
Phase 2, Multi-Center Trial of Modafinil for Methamphetamine Dependence
NCT00520286
PET Imaging of Nicotinic Acetylcholine Receptors
NCT01046513
Evaluating Alternative Aftercare Models for Ex-offenders
NCT01586689
Screening Protocol for the Evaluation of Potential Research Subjects
NCT01036971
Effects of Nicotine on Elements of Attentions in Smokers and Nonsmokers
NCT01034020
Emergency Department Initiated Tobacco Treatment (EDITT)
NCT00252902
Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms
NCT01603992
Dopamine Function and Reward Processing In Schizophrenia
NCT01035996
Effectiveness of Selegiline in Treating Marijuana Dependent Individuals - 1
NCT00218517
Effectiveness of Bupropion for Treating Nicotine Dependence in Young People
NCT00129272
Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency Management
NCT00292110
Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1
NCT00218556
Positive Choice: Prevention for Positive Health
NCT00447707
Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11
NCT00015301
Bupropion for the Treatment of Methamphetamine Dependence - 1
NCT00069251
Effectiveness of N-acetylcysteine in Treating Cocaine Dependent Individuals - 1
NCT00136825
Comparison of Buprenorphine and Methadone - 3
NCT00000334
Cocaethylene as a Treatment for Cocaine Dependence - 1
NCT00124696
Effectiveness of Using Tobacco Free Snuff in Reducing Negative Effects of Smokeless Tobacco Use
NCT00218270
Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals
NCT00870792
Effects of Nicotine on Brain Activity as Measured by fMRI
NCT01037153
Clonidine as Adjunct Therapy for the Treatment of Neonatal Abstinence Syndrome
NCT00510016
Effects of Buspirone in Opiate Withdrawal
NCT00326235
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
NCT00218127
Evaluation of Benztropine for Cocaine Craving - 2
NCT00000333
Ondansetron for the Treatment of Cocaine Dependence - 1
NCT00033085
Randomized Trial of the Positive Action Program in Hawaii Schools
NCT00328445
Reduction of Smoking in Cardiac Disease Patients
NCT00469885
Physiological, Cognitive and Cerebral Activity Changes as a Function of Cigarette Smoking (With or Without Nicotine) and Tobacco Abstinence
NCT01034384
Naltrexone Augmentation of Nicotine Patch Therapy - 1
NCT00218153
Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14
NCT00015340
Progesterone Treatment in Female Smokers - 12
NCT00000295
Cocaine-Methylphendidate Interaction Study - 4
NCT00015067
Effects of Labetalol on Human Cocaine Use - 8
NCT00000291
Buprenorphine Detoxification - BBDVI - 19
NCT00000237
Tyrosine for Methamphetamine Dependence - 1
NCT00000322
Modeling Impaired Judgement in Cocaine Abusers - 6
NCT00015236
The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1
NCT00158288
Prepulse Inhibition of Startle in Cocaine Dependence - 7
NCT00015249
Buprenorphine and Naloxone Combination Study - 10
NCT00015288
Cocaine Abuse and ADHD - 10
NCT00000275
Therapeutic Potential of Kappa-Opioids Against Cocaine - 1
NCT00000323
Risperidone for the Treatment of Cocaine Dependence - 7
NCT00000342
Role of Metabolites in Nicotine Dependence (2) - 5
NCT00000288
Cocaine Abuse and Attention Deficit Disorder - 3
NCT00000268
Role of Metabolites in Nicotine Dependence (1) - 1
NCT00000284
Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1
NCT00000318
Alternate-Day Buprenorphine Administration. Phase VII - 8
NCT00000226
Flupenthixol Treatment in Schizophrenic Cocaine Abusers - 1
NCT00000266
Flupenthixol Decanoate in Methamphetamine Smoking - 1
NCT00000241
Buprenorphine Maintenance for Opiate Dependence - 6
NCT00000357
Pharmacological Modulation of Cocaine Effects - 1
NCT00000201
Risperidone Treatment in Dually-Diagnosed Individuals - 2
NCT00000267
Buprenorphine Pharmacology Related to Addiction Treatment - 18
NCT00000236
Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7
NCT00000358
Study Comparing Liquid and Tablet Buprenorphine Formulations - 5
NCT00000302
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 31 |
| Phase 3 | 30 |
| Phase 4 | 4 |
What the Pipeline for National Institute on Drug Abuse (NIDA) Shows
According to the ClinicalTrials.gov registry, National Institute on Drug Abuse (NIDA) is linked to 108 US clinical trials across every stage of research activity. Of those, 41 studies are currently recruiting — about 38% of the sponsor's indexed portfolio — and 67 are already marked complete, representing roughly 62% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for National Institute on Drug Abuse (NIDA) reports 34 late-stage studies (Phase 3 and Phase 4 combined) and 47 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for National Institute on Drug Abuse (NIDA) is Cocaine-Related Disorders with 17 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.